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Abstract
Background: Previous findings have suggested that epigenetic-mediated HLA-G expression in
tumor cells may be associated with resistance to host immunosurveillance. To explore the
potential role of DNA methylation on HLA-G  expression in ovarian cancer, we correlated
differences in HLA-G expression with methylation changes within the HLA-G regulatory region in an
ovarian cancer cell line treated with 5-aza-deoxycytidine (5-aza-dC) and in malignant and benign
ovarian tumor samples and ovarian surface epithelial cells (OSE) isolated from patients with normal
ovaries.
Results: A region containing an intact hypoxia response element (HRE) remained completely
methylated in the cell line after treatment with 5-aza-dC and was completely methylated in all of
the ovarian tumor (malignant and benign) samples examined, but only variably methylated in normal
OSE samples. HLA-G expression was significantly increased in the 5-aza-dC treated cell line but no
significant difference was detected between the tumor and OSE samples examined.
Conclusion: Since HRE is the binding site of a known repressor of HLA-G expression (HIF-1), we
hypothesize that methylation of the region surrounding the HRE may help maintain the potential
for expression of HLA-G in ovarian tumors. The fact that no correlation exists between methylation
and HLA-G gene expression between ovarian tumor samples and OSE, suggests that changes in
methylation may be necessary but not sufficient for HLA-G expression in ovarian cancer.
Background
Classic and non-classic HLA (human leukocyte antigen)
class I genes play a central role in the regulation of the
immune response. The non-classic HLA-G  gene is
expressed in a variety of tissues but perhaps most notably
in the fetal-maternal interface on the extravillous cytotro-
phoblast and has been postulated to help protect the fetus
from maternal allorecognition [1]. This hypothesis is sup-
ported by subsequent studies demonstrating that HLA-G
proteins can suppress a variety of immune functions
including natural killer (NK) cell-mediated cytolysis and
the T-cell proliferative response [2,3]. Recent findings
indicate that HLA-G antigens are present in ovarian and
various other types of malignant cells and tissues [4-7].
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These findings and others have led to the hypothesis that
induction of HLA-G expression in tumor cells may con-
tribute to their avoidance of immunosurveillance by the
host [8,9] (but disputed by [10]).
Sequences known to be involved in the transcriptional
regulation of most HLA class I genes are disrupted in the
HLA-G  gene raising questions as to the mechanisms
underlying HLA-G expression [11-13]. Studies conducted
in a variety of human cancer cell lines suggest that epige-
netic mechanisms may play an important role in HLA-G
expression [14,15]. To explore the potential role of DNA
methylation on HLA-G expression in ovarian cancer, we
tested the effect of the methylation inhibitor 5-aza-deoxy-
cytidine on methylation within the CpG-enriched regula-
tory region of the HLA-G gene and correlated changes in
expression in an ovarian cancer cell line. The results dem-
onstrate that 5-aza-dC treatment results in hypomethyla-
tion of putative control sequences within the 5' regulatory
region of HLA-G and that these changes in methylation
correlate with a significant increase in expression. A nota-
ble exception was a region (-211 to -290) containing a
hypoxia response element (HRE; [16]) that remained
completely methylated.
Methylation within the regulatory region of the HLA-G
gene also was examined in eighteen malignant and
benign ovarian tumor samples and in ovarian surface epi-
thelial cells (OSE) isolated from four patients with normal
ovaries. A number of significant differences in levels of
methylation of sequences within the 5' regulatory region
were detected between the tumor samples and the normal
surface epithelial cells. Interestingly, the region contain-
ing the HRE (-211 to -290) that remained methylated in
5-aza-dC treated BG-1 cells was also completely methyl-
ated in all ovarian tumor samples, but not in OSE con-
trols, suggesting strong selection against accessibility to
the HRE in ovarian tumor cells. Although the highest lev-
els of HLA-G expression were associated with tumor sam-
ples, no significant overall correlation between
methylation and expression levels was detected by real
time RT-PCR. Our results indicate that alterations in
methylation may be necessary but not sufficient for HLA-
G expression in ovarian tumors.
Results
5-aza-dC treatment of ovarian cancer cells (BG-1) results 
in hypomethylation of sequences within the HLA-G 
regulatory region and correlates with an increase in gene 
expression
Previous studies have shown that 5-aza-deoxycytidine
treatment of a variety of tumor (glioma, choriocarcinoma,
B-lymphoma and melanoma) cell lines results in signifi-
cant hypomethylation of a CpG-rich region located
within 450 bp 5' of the HLA-G start codon and correlates
with a significant increase in HLA-G expression [15]. To
determine if ovarian tumor cells would show a similar
response, we selected an ovarian cancer cell line (BG-1)
that did not display HLA-G expression prior to treatment
(Figure 1). Sodium bisulfite modification and subsequent
sequencing was carried out on 10 clones each of genomic
DNA isolated from 5-aza-dC treated and untreated BG-1
cells. The results demonstrate that while all 19 CpG sites
located within the 450 bp region 5' of the HLA-G start
codon were methylated in untreated cells, there was a
36% overall decrease of methylation in treated cells (Fig-
ure 2). The approximately 200 bp region immediately 5'
to the transcriptional start site (-8 to -188) that encom-
passes HLA-G cis-regulatory sequences was significantly (p
= 0.001) hypomethylated, but a 79 bp region (-211 to -
290) remained methylated after 5-aza-dC treatment in all
of the clones examined. Correlated with the 5-aza-dC
induced changes in methylation patterns, there was an
increase in HLA-G expression (Figure 1).
Methylation within the HLA-G 5' regulatory region 
significantly differs between ovarian surface epithelial cells 
(OSEs) and benign and malignant ovarian tumors
Epithelial ovarian carcinomas are believed to derive from
ovarian surface epithelial cells (OSE) or epithelial cells
lining the inner surface of inclusion cysts [17,18]. To
determine if methylation within the 5' regulatory region
of the HLA-G gene differs among OSE and benign and
malignant ovarian tumors, we performed sodium
bisulfite genomic sequencing of DNA isolated from laser
capture microdissected (LCM) tumor cells from 9 adeno-
mas and 9 adenocarcinomas and OSE brushings from the
Activation of HLA-G gene transcription in the BG-1 cell line  treated with 5-aza-deoxycytidine (5-aza-dC) Figure 1
Activation of HLA-G gene transcription in the BG-1 
cell line treated with 5-aza-deoxycytidine (5-aza-dC). 
Results of semi-quantitative RT-PCR (reverese transcriptase-
polymerase chain reaction) on the ovarian carcinoma cell line 
BG-1, either untreated (control) or treated with 50 μM 5-
aza-deoxycytidine (5-aza-dC). ("-" = samples without RT; "+" 
= samples with RT). GAPDH was used as an endogenous con-
trol.Molecular Cancer 2008, 7:43 http://www.molecular-cancer.com/content/7/1/43
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Methylation analysis of the HLA-G promoter in the control and 5-aza-dC treated BG-1 cell line Figure 2
Methylation analysis of the HLA-G promoter in the control and 5-aza-dC treated BG-1 cell line. (A) Schematic 
map of 450 bp of the HLA-G promoter region. Colored boxes represent enhancers and regulator binding sites: HRE = hypoxia 
response element; B2 = enhancer κB2; B1 = enhancer κB1; ISRE = interferon sequence responsive element; W/S= W/S box; 
X1 = conserved X1 regulatory box; X2 = X2 box; CAAT = CCAAT box; TATA = TATA box; ex1 = exon 1; Met-F and Met-R 
= forward (F) and reverse (R) primer binding sites. (B) Bisulfite genomic sequencing of 19 CpG dinucleotides of the region 
from -450 to ATG. Individual CpG dinulcotides are depicted as circles. Each row of circles represents an individual sequenced 
clone, either untreated (PBS) or treated with 50 μM 5-aza-dC (open circle = 100% unmethylated; filled circle = 100% methyl-
ated; %MET = percentage of methylation of each individual clone; %CONV = efficiency of sodium bisulfite treatment).
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normal ovaries of 4 patients undergoing hysterectomies
for reasons unrelated to ovarian cancer. Five to eight
clones were sequenced from each DNA sample. The aver-
age % methylation for all 19 CpG sites located from 8 to
394 bp 5' to the HLA-G transcriptional start site is pre-
sented in Table 1 and Figure 3.
Average methylation levels across the 450 bp 5' region
examined were variable among samples, ranging from
26.3% to 55.3%. The malignant and benign tumor sam-
ples displayed nearly identical average methylation levels
across the region (adenocarcinomas 45.9%; adenomas
45.1%) while average methylation levels (35.5%) were
significantly lower for the OSE samples (adenocarcinoma
vs. OSE, p = 0.022; adenoma vs. OSE, p = 0.007, unpaired
t-test). The same region (CpG sites -211 to -290) that
remained methylated after 5-aza-dC treatment in the BG-
1 cell line was uniformly hypermethylated in all of the
tumor samples, but variably methylated in the OSE sam-
ples.
Examination of the methylation levels between the
benign and malignant tumor samples at each of the 19
individual CpG sites displayed no significant differences
(Table 1). However, 12 of the 19 sites displayed signifi-
cant differences between the OSE and tumor samples
(Table 1). The OSE samples displayed significantly higher
levels of methylation than tumor samples at 5 (-60, -65, -
125, -356 and -394) of the 19 CpG sites examined. OSE
samples displayed significantly lower levels of methyla-
tion than tumor samples at 7 (-121, -150, -211, -241, -
261, -272, and -290) of the 19 CpG sites examined.
We also examined a second 399 bp region of the HLA-G
CpG island from -7 to + 392 extending into Exon 2. This
region contains 42 CpG dinucleotides. No significant dif-
Table 1: Methylation status of 19 CpG sites in the 450 bp promoter region of HLA-G gene in malignant (CA), benign (BN) and normal 
(NL) ovarian tissue samples.
CA -394 -356 -290 -272 -261 -241 -211 -188 -186 -150 -125 -121 -68 -65 -62 -60 -39 -27 -8
212 0 0 1 1 1 1 1 0.00 0.00 0.25 0.00 0.25 0.75 0.00 0.75 0.00 0.00 0.00 0.75
229 0 0 1 1 1 1 1 0.00 0.00 1.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
183 0 0 1 1 1 1 1 0.00 0.00 0.38 0.00 0.38 0.63 0.00 0.63 0.00 0.00 0.00 0.63
317 0 0 1 1 1 1 1 0.60 0.60 0.80 0.00 0.80 0.20 0.20 0.80 0.00 0.60 0.00 0.40
369 0 0 1 1 1 1 1 0.40 0.40 0.60 0.20 0.60 0.40 0.00 1.00 0.20 0.60 0.00 0.20
413 0 0 1 1 1 1 1 0.60 0.60 1.00 0.00 0.80 0.00 0.00 0.80 0.00 0.60 0.00 0.20
170 0 0 1 1 1 1 1 0.20 0.20 1.00 0.00 1.00 0.00 0.00 0.20 0.00 0.20 0.00 0.00
228 0 0 1 1 1 1 1 0.75 0.75 0.75 0.00 0.75 0.25 0.25 1.00 0.00 0.75 0.00 0.25
242 0 0 1 1 1 1 1 0.20 0.20 0.40 0.00 0.40 0.60 0.00 0.80 0.00 0.20 0.00 0.80
AVE 0.000 0.000 1.000 1.000 1.000 1.000 1.000 0.306 0.306 0.687 0.022 0.664 0.314 0.050 0.664 0.022 0.328 0.000 0.359
BN
382 0 0 1 1 1 1 1 0.00 0.00 0.40 0.00 0.40 0.60 0.00 0.60 0.00 0.00 0.00 0.80
412 0 0 1 1 1 1 1 0.60 0.80 0.80 0.00 0.80 0.20 0.00 0.83 0.00 0.60 0.00 0.00
388 0 0 1 1 1 1 1 0.17 0.17 0.17 0.00 0.17 0.67 0.00 1.00 0.00 0.33 0.00 0.83
416 0.20 0 1 1 1 1 1 0.40 0.40 0.60 0.00 0.60 0.40 0.00 0.80 0.00 0.40 0.00 0.60
371 0.14 0 1 1 1 1 1 0.14 0.14 0.43 0.00 0.43 0.57 0.00 0.71 0.00 0.29 0.00 0.71
377 0.20 0.20 0.60 1 1 1 1 0.40 0.60 0.60 0.20 0.60 0.20 0.00 0.60 0.00 0.60 0.00 0.00
386 0.20 0 1 1 1 1 1 0.00 0.00 0.60 0.00 0.60 0.40 0.00 0.40 0.00 0.00 0.00 0.40
400 0 0 1 1 1 1 1 0.20 0.50 0.50 0.00 0.50 0.50 0.00 1.00 0.00 0.50 0.00 0.50
383 0 0 1 1 1 1 1 0.10 0.10 0.90 0.00 0.90 0.10 0.00 0.30 0.00 0.10 0.00 0.13
AVE 0.082 0.022 0.956 1.000 1.000 1.000 1.000 0.223 0.301 0.556 0.022 0.556 0.404 0.000 0.694 0.000 0.313 0.000 0.441
NL
492 0.40 0.40 0.40 0.60 0.80 1.00 0.80 0.00 0.20 0.20 0.20 0.20 0.40 1.00 0.20 0.20 0.00 0.00 0.20
499 0.17 0.33 0.50 0.67 0.83 0.67 0.83 0.50 0.00 0.33 0.50 0.50 0.50 0.50 0.67 0.17 0.00 0.00 0.17
500 0.60 0.80 0.00 0.80 0.40 0.80 0.80 0.00 0.00 0.20 0.20 0.20 0.00 0.00 0.00 0.00 0.20 0.00 0.00
525 0.33 0.33 0.00 1.00 1.00 1.00 0.67 0.00 0.00 0.00 0.33 0.33 0.33 0.33 0.67 0.00 0.00 0.33 0.33
AVE 0.374 0.466 0.225 0.767 0.758 0.867 0.776 0.125 0.050 0.183 0.308 0.308 0.308 0.458 0.384 0.092 0.050 0.083 0.174
P-VALUES
CA VS NL <1E-04 <1E-04 <1E-04 0.001 0.011 0.025 <1E-04 0.308 0.122 0.008 0.0004 0.033 0.970 0.014 0.225 0.174 0.111 0.139 0.277
BN VS NL 0.003 0.0002 <1E-04 0.001 0.011 0.025 <1E-04 0.466 0.121 0.010 0.0004 0.063 0.448 0.005 0.087 0.019 0.059 0.139 0.153
Values shown for each sample/position are the average of 5–8 clones. Significance of differences at each CpG site between tumor and normal 
samples are shown.Molecular Cancer 2008, 7:43 http://www.molecular-cancer.com/content/7/1/43
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Methylation analysis of the HLA-G promoter in tumor and normal ovarian samples Figure 3
Methylation analysis of the HLA-G promoter in tumor and normal ovarian samples. (A) Schematic map of 450 bp 
of the HLA-G promoter region (See Figure 2 legend for symbols). (B) Bisulfite genomic sequencing of 19 CpG dinucleotides of 
the region from -450 to the transcription start site is analyzed for 18 ovarian adenocarcinomas (red) and benign adenomas 
(green) and four normal ovaries (black). Five to eight clones were sequenced for each sample and each circle represents the 
average methylation for a single CpG dinucleotide (open circle = 100% unmethylated; filled circle = 100% methylated; %M = 
percentage of total methylation per sample).
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Table 2: Methylation status of 42 CpG sites in a 399 bp region of HLA-G gene extending from the transcriptional start site (TSS) into 
Exon II (-7 to +392) in malignant (CA), benign (BN) and normal (NL) ovarian tissue samples.
CA +18 +40 +59 +70 +80 +97 +106 +108 +124 +129 +132 +138 +147 +154 +156 +159 +171
2 1 2 0 . 6 30 . 5 00 . 5 00 . 5 00 . 5 00 . 7 50 . 6 30 . 6 30 . 5 00 . 0 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 0
1 8 3 0 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 0 00 . 5 00 . 5 00 . 5 00 . 0 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 0
3 6 9 0 . 8 00 . 9 00 . 9 00 . 8 00 . 8 00 . 8 00 . 8 00 . 8 00 . 5 80 . 0 00 . 8 00 . 7 00 . 6 80 . 8 00 . 6 80 . 8 00 . 6 8
2 4 2 0 . 3 80 . 3 90 . 4 50 . 3 90 . 3 20 . 2 50 . 1 30 . 3 20 . 3 20 . 2 50 . 3 20 . 3 20 . 3 20 . 3 20 . 3 20 . 3 20 . 3 2
1 7 0 1 . 0 00 . 6 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 8 80 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
4 1 3 1 . 0 01 . 0 01 . 0 01 . 0 00 . 9 30 . 5 01 . 0 00 . 8 81 . 0 00 . 0 01 . 0 01 . 0 01 . 0 00 . 8 81 . 0 01 . 0 01 . 0 0
3 1 7 0 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 5 00 . 8 80 . 8 80 . 8 80 . 0 00 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 8
2 2 8 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 0 00 . 5 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
A V E 0 . 7 70 . 7 20 . 7 80 . 7 60 . 7 40 . 6 00 . 7 40 . 7 50 . 7 10 . 0 30 . 6 90 . 7 40 . 7 30 . 7 30 . 7 30 . 7 50 . 7 3
BN
3 8 2 0 . 5 80 . 7 10 . 5 80 . 5 80 . 4 60 . 5 00 . 5 80 . 5 80 . 7 30 . 0 00 . 5 80 . 5 80 . 5 80 . 5 80 . 5 80 . 5 80 . 5 8
4 1 2 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 7 51 . 0 01 . 0 00 . 7 50 . 1 30 . 6 30 . 7 51 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
3 8 8 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 5 01 . 0 00 . 6 31 . 0 00 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
4 1 6 0 . 5 00 . 6 70 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 0 00 . 5 00 . 5 00 . 1 70 . 5 00 . 5 00 . 5 00 . 5 0
3 7 1 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 8 30 . 1 71 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
3 7 7 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 3 81 . 0 00 . 8 80 . 7 50 . 1 70 . 8 80 . 8 80 . 8 81 . 0 01 . 0 00 . 8 81 . 0 0
3 8 6 1 . 0 01 . 0 01 . 0 01 . 0 00 . 8 80 . 8 81 . 0 01 . 0 00 . 7 10 . 5 00 . 8 30 . 8 30 . 8 31 . 0 01 . 0 01 . 0 01 . 0 0
4 0 0 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 6 70 . 6 70 . 7 00 . 0 00 . 5 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
3 8 3 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 0 01 . 0 01 . 0 01 . 0 00 . 0 00 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
A V E 0 . 9 00 . 9 30 . 9 00 . 9 00 . 8 70 . 6 10 . 8 60 . 8 10 . 7 80 . 1 10 . 6 60 . 8 40 . 8 30 . 9 00 . 9 00 . 8 80 . 9 0
NL
5 0 0 1 . 0 00 . 8 30 . 8 30 . 8 31 . 0 00 . 6 70 . 8 30 . 8 31 . 0 00 . 0 00 . 8 30 . 8 30 . 5 00 . 5 00 . 3 30 . 5 00 . 5 0
5 2 5 0 . 7 50 . 7 50 . 6 30 . 7 50 . 7 50 . 5 00 . 7 50 . 8 80 . 7 50 . 0 00 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 6 3
4 9 2 0 . 6 30 . 5 00 . 5 00 . 5 00 . 5 00 . 2 50 . 6 30 . 6 30 . 6 30 . 0 00 . 6 30 . 5 00 . 6 30 . 6 30 . 6 30 . 6 30 . 7 5
4 9 9 0 . 7 50 . 7 10 . 5 80 . 7 10 . 5 80 . 2 90 . 8 80 . 8 80 . 5 40 . 0 00 . 7 10 . 7 10 . 8 80 . 5 80 . 7 10 . 7 10 . 8 8
AVE 0.78 0.70 0.64 0.70 0.71 0.43 0.77 0.80 0.73 0.00 0.73 0.70 0.69 0.61 0.60 0.65 0.69
P-VALUES
CA VS NL 0.946 0.869 0.322 0.673 0.838 0.390 0.857 0.690 0.879 0.506 0.766 0.795 0.762 0.403 0.415 0.487 0.762
BN VS NL 0.332 0.018 0.041 0.105 0.255 0.320 0.446 0.990 0.660 0.235 0.671 0.220 0.380 0.025 0.032 0.051 0.10
CA +175 +193 +227 +230 +233 +240 +245 +249 +251 +261 +269 +281 +287 +292 +299 +303 +308
2 1 2 0 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 3 80 . 0 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 3 80 . 5 00 . 5 0
1 8 3 0 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 0
3 6 9 0 . 5 80 . 6 80 . 8 00 . 8 00 . 8 00 . 8 00 . 8 00 . 9 00 . 8 00 . 7 00 . 8 00 . 8 00 . 8 00 . 8 00 . 8 00 . 8 00 . 6 8
2 4 2 0 . 3 20 . 3 20 . 4 60 . 3 90 . 3 90 . 3 90 . 3 20 . 3 20 . 3 20 . 3 90 . 4 60 . 3 20 . 3 20 . 3 20 . 2 00 . 3 20 . 3 9
1 7 0 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 6 31 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
4 1 3 1 . 0 01 . 0 00 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 7 50 . 8 80 . 7 50 . 8 80 . 8 80 . 6 31 . 0 01 . 0 01 . 0 01 . 0 0
3 1 7 0 . 8 80 . 3 81 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 5 01 . 0 01 . 0 01 . 0 0
2 2 8 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
A V E 0 . 7 20 . 6 70 . 7 70 . 7 60 . 7 60 . 7 60 . 7 50 . 7 30 . 6 90 . 6 80 . 7 70 . 7 50 . 7 20 . 7 00 . 7 30 . 7 70 . 7 6
BN
3 8 2 0 . 5 80 . 5 80 . 5 80 . 5 80 . 5 80 . 5 80 . 5 80 . 5 80 . 4 60 . 5 80 . 7 10 . 5 80 . 4 60 . 5 80 . 5 80 . 5 80 . 5 8
4 1 2 0 . 6 31 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
3 8 8 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 7 51 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
4 1 6 0 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 6 7
3 7 1 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 1 71 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
3 7 7 1 . 0 00 . 8 81 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 8 81 . 0 00 . 8 81 . 0 01 . 0 00 . 8 81 . 0 01 . 0 01 . 0 01 . 0 0
3 8 6 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 8 31 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 8 8Molecular Cancer 2008, 7:43 http://www.molecular-cancer.com/content/7/1/43
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4 0 0 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 00 . 7 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
3 8 3 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
A V E 0 . 8 60 . 8 80 . 9 00 . 9 00 . 9 00 . 8 60 . 9 00 . 8 80 . 8 80 . 7 50 . 9 10 . 9 00 . 8 70 . 9 00 . 9 00 . 9 00 . 9 0
NL
5 0 0 0 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 8 30 . 5 00 . 5 00 . 5 00 . 5 0
5 2 5 0 . 7 50 . 6 30 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 8 80 . 6 30 . 6 30 . 7 50 . 7 50 . 7 5
4 9 2 0 . 7 50 . 8 80 . 7 50 . 7 50 . 6 30 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 6 30 . 7 50 . 6 3
4 9 9 0 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 8
AVE 0.72 0.72 0.72 0.72 0.69 0.72 0.72 0.72 0.72 0.72 0.72 0.75 0.77 0.69 0.69 0.72 0.69
P-VALUES
CA VS NL 0.986 0.776 0.725 0.784 0.640 0.784 0.840 0.941 0.877 0.788 0.725 0.998 0.720 0.923 0.799 0.780 0.650
BN VS NL 0.283 0.200 0.148 0.148 0.096 0.241 0.148 0.173 0.222 0.865 0.096 0.250 0.427 0.100 0.100 0.148 0.053
CA +314 +319 +322 +328 +340 +342 +346 +349
2 1 2 0 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 0
1 8 3 0 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 0
3 6 9 0 . 8 00 . 8 00 . 8 00 . 8 00 . 8 00 . 8 00 . 8 00 . 8 0
2 4 2 0 . 3 20 . 3 90 . 3 20 . 4 50 . 4 50 . 4 50 . 4 50 . 4 5
1 7 0 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
4 1 3 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
3 1 7 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
2 2 8 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
AVE 0.77 0.77 0.77 0.78 0.78 0.78 0.78 0.78
BN
3 8 2 0 . 5 80 . 5 80 . 5 80 . 5 80 . 5 80 . 5 80 . 5 80 . 5 8
4 1 2 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
3 8 8 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
4 1 6 0 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 00 . 5 0
3 7 1 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
3 7 7 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
3 8 6 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
4 0 0 1 . 0 01 . 0 00 . 8 31 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
3 8 3 1 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 01 . 0 0
AVE 0.90 0.90 0.88 0.90 0.90 0.90 0.90 0.90
NL
5 0 0 0 . 5 00 . 5 00 . 5 00 . 3 30 . 5 00 . 5 00 . 5 00 . 5 0
5 2 5 0 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 5
4 9 2 0 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 50 . 7 51 . 0 0
4 9 9 0 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 80 . 8 8
AVE 0.72 0.72 0.72 0.68 0.72 0.72 0.72 0.78
P-VALUES
CA VS NL 0.769 0.714 0.769 0.515 0.671 0.671 0.671 0.998
BN VS NL 0.148 0.148 0.190 0.120 0.148 0.148 0.148 0.365
Values shown for each sample/position are the average of 5–8 clones. Marginally significant differences between tumor and normal samples were 
detected at 4 of the 42 CpG sites.
Table 2: Methylation status of 42 CpG sites in a 399 bp region of HLA-G gene extending from the transcriptional start site (TSS) into 
Exon II (-7 to +392) in malignant (CA), benign (BN) and normal (NL) ovarian tissue samples. (Continued)Molecular Cancer 2008, 7:43 http://www.molecular-cancer.com/content/7/1/43
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ference overall in levels of methylation between OSE and
malignant or benign ovarian tumor samples was detected
within this region (p < 0.05; Table 2).
No significant difference in HLA-G expression was 
detected between OSE and malignant and benign ovarian 
tumor samples
To determine if levels of HLA-G expression are signifi-
cantly different between ovarian tumors and OSE cells, we
determined relative expression levels (real time RT-PCR)
of 3 OSE samples and tumor cells isolated by LCM from 4
malignant and 4 benign ovarian tumor samples. The
results presented in Table 3 indicate that HLA-G expres-
sion levels are highly variable among all samples and no
consistent or significant differences in HLA-G expression
were detected between the OSE and tumor samples. Our
results are consistent with previous reports of high varia-
bility in HLA-G expression within and between tumors
[7,10]. Thus, the significant difference in methylation lev-
els within the promoter region observed between OSE
and the ovarian tumor samples was not correlated with
differences in HLA-G expression.
Discussion
Contrary to other HLA molecules, HLA-G regulation is
only partially understood. Studies of the methylation lev-
els of 450 bp of the promoter region of HLA-G  in
melanoma and choriocarcinoma cell lines showed a cor-
relation between expression and low levels of methylation
[15]. In our study we looked at the same region in the
ovarian cancer cell line BG-1, which showed almost com-
plete methylation of all CpG dinucleotides and no expres-
sion of HLA-G. Treatment of the cells with the
methylation inhibitor, 5-aza-dC, resulted in a significant
decrease in levels of methylation at the HLA-G promoter
region that correlated with an increase in levels of HLA-G
expression (Figures 1 and 2). Consistent with previously
published studies conducted with other cancer cell lines
[14,15], our results suggest that the methylation status of
the HLA-G promoter region may be important for the con-
trol of HLA-G expression in ovarian cancer.
To test this hypothesis in tissues, we analyzed methylation
of the HLA-G 5' regulatory region in 4 OSE samples and
18 malignant and benign ovarian tumor samples. In addi-
tion, we measured the relative levels of HLA-G expression
in 11 OSE and ovarian tumor samples from which cancer
cells were isolated using laser capture microdissection
(LCM). We found that there were significant differences in
levels of methylation within the 5' HLA-G  regulatory
region between OSE and the malignant and benign ovar-
ian tumor samples, but no significant difference between
the malignant and benign tumor samples. This observa-
tion is consistent with the view that any putative adaptive
advantage imparted to tumor cells by HLA-G apparently
does not distinguish between malignant and benign
tumor cells.
We found that many of the CpG sites displaying a signifi-
cant decrease in methylation in the tumor samples were
located in proximity to intact binding sites of regulatory
proteins known to serve as activators of gene expression
(CCAAT box -76 and an intact SP1 and RFX binding site
within the X1 box at -130 [13,19]; Figure 3). Hypometh-
ylation of these sites in ovarian tumors may serve to
potentiate HLA-G expression. In contrast, we observed a
significant increase in levels of methylation in tumor sam-
ples at CpG sites located in proximity to a hypoxia
response element [16] located 243 bp upstream of the
HLA-G transcriptional start site. Interestingly, this same
region remained methylated in 5-aza-dC treated BG-1
cells, suggesting that strong selection may operate to pre-
vent binding to the HRE in ovarian tumor cells.
HRE is the binding site of HIF-1, a protein that plays a crit-
ical role in the cellular response to hypoxia, with the
potential to act as either a positive or negative regulatory
factor [20-22]. Evidence has recently been reported that
HIF-1 may act as a negative regulator of HLA-G expression
in some human melanoma (FON) and choriocarcinoma
(JEG-3) cell lines [22] The functional significance of the
methylation of the CpG island surrounding the HIF-1
binding site in the ovarian tumor samples remains to be
determined. However, preventing the binding of a poten-
Table 3: Real-time RT-PCR analysis of HLA-G expression in ovarian samples.
ADENOCARCINOMAS ADENOMAS NORMAL
Patient Expression FIGO Stage Patient Expression Patient Expression
242 0.42 IIIc 386 0.67 500 3.50
369 3.05 IIIc 371 0.83 492 20.53
183 4.03 IIIc 416 3.54 525 53.71
212 177.01 IIIc 382 13.36
AVE 46.13 AVE 4.60 AVE 25.91
SD 87.27 SD 5.98 SD 25.53Molecular Cancer 2008, 7:43 http://www.molecular-cancer.com/content/7/1/43
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tial repressor protein (HIF-1) may help maintain the tran-
scription of HLA-G  in ovarian tumors under hypoxic
conditions thus allowing the tumor cells to evade cyto-
toxic T lymphocyte recognition and destruction.
It is important to keep in mind that the postulated signif-
icance of methylation changes in gene regulatory regions
is the increased (hypomethylation) or decreased (hyper-
methylation) access it provides for the binding of proteins
or protein complexes that regulate gene expression [23].
Thus, although methylation changes in gene regulatory
regions may be necessary for subsequent changes in levels
of expression, these changes in methylation alone may
not be sufficient to effect expression changes. The fact that
the significant differences in methylation we observed
between OSE and ovarian tumor samples do not correlate
with differences in HLA-G expression may serve to under-
lie this distinction. Our results are consistent with a sce-
nario whereby changes in methylation in ovarian tumor
cells potentiate them for HLA-G transcriptional activation
(or avoidance of transcriptional repression) by regulatory
proteins induced by micro-environmental or mutational
changes in specific tumor cell lineages.
Conclusion
Differences in methylation within the 5' regulatory region
of HLA-G were detected between normal ovarian surface
epithelial cells and ovarian cancers. The most striking dif-
ference was in a region (-211 to -290 from HLA-G TSS),
containing an intact hypoxia response element (HRE).
This region was completely methylated in all of the ovar-
ian tumor (malignant and benign) samples examined, but
was only variably methylated in normal surface epithelial
cells. Interestingly, this same region remained completely
methylated in an ovarian cancer cell line (BG-1) after
treatment with 5-aza-dC suggesting that there is strong
selection against loss of methylation in this region in
these ovarian cancer cells. Since HRE is the binding site of
a known repressor of HLA-G  expression (HIF-1), we
hypothesize that methylation of the region surrounding
the HRE may help maintain the potential for expression
of HLA-G in ovarian tumors. The fact that no correlation
exists between methylation and HLA-G gene expression
between ovarian tumor samples and OSE, leads us to con-
clude that changes in methylation may be necessary but
not sufficient for HLA-G expression in ovarian cancer.
Methods
Tissue samples
Ovarian tumor samples were collected at Northside Hos-
pital (Atlanta, GA) during surgery and snap frozen in liq-
uid nitrogen within 1 minute of removal from patients.
Brushings of normal ovarian surface epithelial cells (OSE)
were preserved in RNAlater (Ambion, Austin, GA) within
1 minute of removal from patients. Patient consent and
approval from the Institutional Review Boards of the Uni-
versity of Georgia, Georgia Institute of Technology, and
Northside Hospital were obtained. Pathological and clin-
ical information of samples is presented in Table 4.
Human cell-line culture
The BG-1 ovarian adenocarcinoma cell line was kindly
provided by JM Hall and KS Korach (NIH). Cells were
propagated in DMEM: F12/50:50 (Invitrogen, Carlsbad,
CA), supplemented with 2 mM L-glutamine (Mediatech
Inc., Herndon, VA), 10% heat inactivated FBS (Invitrogen,
Carlsbad, CA), 1 mM sodium pyruvate (Mediatech Inc.,
Herndon, VA), and 1% penicillin and streptomycin
(Mediatech, Inc., Herndon, VA) at 37°C, 5% CO2 and
~80% relative humidity.
Cell treatments
BG-1 cells were plated at low density 16 hours before
treatment with 50 μM 5-aza-deoxycytidine (Sigma, St.
Louis, MO) for 5 days. On the third day of treatment, the
media was replaced with fresh media containing 5-aza-
dC. Control cells treated with PBS were grown for the
same amount of time.
Laser capture microdissection (LCM)
Fresh frozen tissues from tumors were cut into seven-
micron sections, applied to non-charged slides, then fixed
in 75% ethanol for 30 seconds, stained and dehydrated
using the HistoGene LCM Frozen Section Staining Kit
(Arcturus, Mountain View, CA). LCM was performed with
an AutoPix Automated Laser Capture Microdissection Sys-
tem using the CapSure Macro Caps (Arcturus, Mountain
View, CA). Approximately 10,000 cells were captured on
each of 3–4 caps per sample. Subsequently the DNA was
extracted from captured cells using the PicoPure DNA
Extraction Kit (Arcturus, Mountain View, CA). RNA extrac-
tion from captured cells was carried out using the PicoP-
ure RNA Extraction Kit and amplified with the
RiboAmpHS RNA Amplification Kit (Arcturus, Mountain
View, CA).
DNA and RNA extraction from ovarian surface epithelial 
cells
Epithelial brushings were obtained from normal ovaries
and kept in RNAlater (Qiagen, Valencia, CA). For DNA
extraction, cells were spun down and re-suspended in lysis
buffer (10 mM Tris HCl, 10 mM EDTA, 0.2% SDS and 50
mM NaCl), with 50 μg/ml RNAse A (Invitrogen, Carlsbad,
CA) and 100 μg/ml Proteinase K (EM Science, Gibbstown,
NJ) overnight at 37°C. DNA was then phenol-extracted
and ethanol precipitated. For RNA extraction, cells were
spun down and Trizol was added, following the manufac-
turer's recommended protocol (Invitrogen, Carlsbad,
CA). cDNA was synthesized from RNA using the Ribo-Molecular Cancer 2008, 7:43 http://www.molecular-cancer.com/content/7/1/43
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AmpHS RNA Amplification Kit (Arcturus, Mountain
View, CA).
RT-PCR
Semi-quantitative
Total RNA was extracted from BG-1 cells by adding 1 ml
of Trizol (Invitrogen, Carlsbad, CA) according to the man-
ufacturer's recommendations, and further purified using
RNEasy Mini Kit (Qiagen, Valencia, CA). Four to six μg of
DNAse-treated RNA (DNA-free; Ambion, Houston, TX)
were used to generate cDNA by oligo-dT reverse transcrip-
tion with the Superscript RT-PCR Kit (Invitrogen,
Carlsbad, CA). Primers that recognize all HLA-G isoforms
were designed from the HLA-G RNA reference sequence
(X12273) at 257F 5'-GGAAGAGGAGACACGGAACA-3'
and 1200R 5'-TCCTGTTCCAGAAAAGGGG-3'. GAPDH
(NM_002046) was used as an endogenous control, using
primers 287F 5'-GAAATCCCATCACCATCTTCCAG-3' and
599R 5'-ATGAGTCCTTCCACGATACAAAAG-3'.
Real-time RT-PCR
Total RNA extracted from LCM captured ovarian tumor
cells and normal OSE cell was converted to amplified
cDNA for real-time RT-PCR. TaqMan Gene Expression
Assays (Applied Biosystems, Foster City, CA) were con-
ducted following manufacturer's protocol for HLA-G
(Hs00365950_g1) and for GAPDH endogenous control
(Hs99999905_m1) using the DNA Engine Opticon Sys-
tem (MJ Research, Waltham, MA). A standard curve of
serial dilutions of a plasmid containing either HLA-G or
GAPDH was established for each assay to obtain a relative
quantification of HLA-G or GAPDH gene expression. For
each sample normalized HLA-G expression values are pre-
sented as the ratio between the target gene (HLA-G) and
the endogenous control (GAPDH).
Sodium bisulfite genomic sequencing
Five hundred nanograms to one microgram of genomic
DNA from the BG-1 cells, LCM captured ovarian tumor
cells and normal OSE cells were modified with sodium
bisulfite according to Herman et al. [24]. For LCM sam-
ples, sodium bisulfite modification was performed by
pooling DNA from 2 to 3 caps per patient sample, and
adding 15 μl of hydroquinone and 200 μl of sodium
bisulfite, as well as 1 μg of Herring Sperm DNA (Promega,
Madison, WI) as a carrier.
Modified DNA was used for PCR with primers for the
CpG-enriched 5' regulatory region of HLA-G [15]. Posi-
tion of the primers from the ATG codon of the HLA-G
gene are: Primer F (-456) 5'-AAGAGTATAGGAGGATAGG-
TAAGG-3' and primer R (-16) 5'-AACACCATAACCAC-
CATCCTTAAC-3'.
A second region of HLA-G from -7 to +392 from the ATG
codon was amplified performing two rounds of PCR. The
first round was done with primers F-5'-GGATT-
TATTTTTTTTAGATGTTAAG-3' and R-5'-ATCTACAAAT-
TCATTCTATCAATCTATAC-3', and then nested PCR was
performed with F-5'-GTTAAGGATGGTGGTTATGGTGTT-
Table 4: Patient samples analyzed in this study
Patient Histology Age FIGO Stage Grade
228 Clear cell adenocarcinoma 55 Ia N/A
317 Serous papillary adenocarcinoma 59 Ic 3
170 Mixed endometrioid/serous papillary adenocarcinoma 57 IIa 2
413 Serous papillary adenocarcinoma 50 IIb 3
212 Mixed endometrioid/serous papillary adenocarcinoma 59 IIIc 3
369 Serous papillary adenocarcinoma 52 IIIc 3
242 Serous papillary adenocarcinoma 64 IIIc 3
229 Serous papillary adenocarcinoma 58 IIIc 3
183 Serous papillary adenocarcinoma 66 IIIc 2
412 Mucinous cystadenoma 65
377 Mucinous cystadenoma 42
383 Mucinous cystadenoma with focal borderline features 75
382 Serous cystadenofibroma 67
386 Serous cystadenofibroma 59
388 Serous cystadenofibroma 53
371 Serous cystadenofibroma 60
400 Serous cystadenofibroma 43
416 Serous cystadenoma 65
492 Normal surface epithelium 38
499 Normal surface epithelium 69
500 Normal surface epithelium 25
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3' and R-5'-TATCTCCTCTTCCCAATACTCCAA-3'. PCR
products were purified using the QIAquick Gel Extraction
Kit (Qiagen, Valencia, CA), and the DNA cloned using
TOPO TA Cloning for Sequencing Kit (Invitrogen,
Carlsbad, CA). DNA plasmids from individual colonies
were extracted using QIAprep Spin Miniprep Kit (Qiagen,
Valencia, CA). Automated sequencing was performed by
Integrated Biotech Laboratories (Athens, GA).
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